View in EDS HTML Full Text PDF Full Text

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.

Saved in:
Bibliographic Details
Title: Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.
Authors: Kosloski MP; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Guttman-Yassky E; Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, USA.; Rockefeller University, New York, New York, USA., Cork MJ; Sheffield Dermatology Research, University of Sheffield, Sheffield, UK.; Sheffield Children's Hospital, Sheffield, UK., Worm M; Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany., Nahm DH; Ajou University Hospital, Suwon, Korea., Zhu X; Formerly Regeneron Pharmaceuticals Inc., Basking Ridge, New Jersy, USA., Ruddy MK; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Harel S; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Kamal MA; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Goulaouic H; Sanofi, Chilly-Mazarin, France., Xu CR; Sanofi, Bridgewater, New Jersey, USA., Avetisova E; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Davis JD; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Nivens MC; Formerly Regeneron Pharmaceuticals, Tarrytown, New York, USA., Shabbir A; Formerly Regeneron Pharmaceuticals, Tarrytown, New York, USA., Radin A; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
Source: Clinical and translational science [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e13874.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39077906
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kosloski+MP%22">Kosloski MP</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Guttman-Yassky+E%22">Guttman-Yassky E</searchLink>; Icahn School of Medicine at Mount Sinai Medical Center, New York, New York, USA.; Rockefeller University, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Cork+MJ%22">Cork MJ</searchLink>; Sheffield Dermatology Research, University of Sheffield, Sheffield, UK.; Sheffield Children's Hospital, Sheffield, UK.<br /><searchLink fieldCode="AU" term="%22Worm+M%22">Worm M</searchLink>; Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Nahm+DH%22">Nahm DH</searchLink>; Ajou University Hospital, Suwon, Korea.<br /><searchLink fieldCode="AU" term="%22Zhu+X%22">Zhu X</searchLink>; Formerly Regeneron Pharmaceuticals Inc., Basking Ridge, New Jersy, USA.<br /><searchLink fieldCode="AU" term="%22Ruddy+MK%22">Ruddy MK</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Harel+S%22">Harel S</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Kamal+MA%22">Kamal MA</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Goulaouic+H%22">Goulaouic H</searchLink>; Sanofi, Chilly-Mazarin, France.<br /><searchLink fieldCode="AU" term="%22Xu+CR%22">Xu CR</searchLink>; Sanofi, Bridgewater, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Avetisova+E%22">Avetisova E</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Davis+JD%22">Davis JD</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Nivens+MC%22">Nivens MC</searchLink>; Formerly Regeneron Pharmaceuticals, Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Shabbir+A%22">Shabbir A</searchLink>; Formerly Regeneron Pharmaceuticals, Tarrytown, New York, USA.<br /><searchLink fieldCode="AU" term="%22Radin+A%22">Radin A</searchLink>; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101474067%22">Clinical and translational science</searchLink> [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e13874.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22WileyBlackwell+Pub%22">WileyBlackwell Pub </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101474067 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1752-8062 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217528054%22">17528054 </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Sci <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39077906
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/cts.13874
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e13874
    Titles:
      – TitleFull: Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kosloski MP
      – PersonEntity:
          Name:
            NameFull: Guttman-Yassky E
      – PersonEntity:
          Name:
            NameFull: Cork MJ
      – PersonEntity:
          Name:
            NameFull: Worm M
      – PersonEntity:
          Name:
            NameFull: Nahm DH
      – PersonEntity:
          Name:
            NameFull: Zhu X
      – PersonEntity:
          Name:
            NameFull: Ruddy MK
      – PersonEntity:
          Name:
            NameFull: Harel S
      – PersonEntity:
          Name:
            NameFull: Kamal MA
      – PersonEntity:
          Name:
            NameFull: Goulaouic H
      – PersonEntity:
          Name:
            NameFull: Xu CR
      – PersonEntity:
          Name:
            NameFull: Avetisova E
      – PersonEntity:
          Name:
            NameFull: Davis JD
      – PersonEntity:
          Name:
            NameFull: Nivens MC
      – PersonEntity:
          Name:
            NameFull: Shabbir A
      – PersonEntity:
          Name:
            NameFull: Radin A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2024 Aug
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1752-8062
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Clinical and translational science
              Type: main
ResultId 1